144 related articles for article (PubMed ID: 27863175)
1. Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs.
Hutchinson LG; Mueller HJ; Gaffney EA; Maini PK; Wagg J; Phipps A; Boetsch C; Byrne HM; Ribba B
CPT Pharmacometrics Syst Pharmacol; 2016 Nov; 5(11):636-645. PubMed ID: 27863175
[TBL] [Abstract][Full Text] [Related]
2. Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy.
Zhang L; Takara K; Yamakawa D; Kidoya H; Takakura N
Cancer Sci; 2016 Jan; 107(1):36-44. PubMed ID: 26475217
[TBL] [Abstract][Full Text] [Related]
3. Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
Mollard S; Ciccolini J; Imbs DC; El Cheikh R; Barbolosi D; Benzekry S
Oncotarget; 2017 Apr; 8(14):23087-23098. PubMed ID: 28416742
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
5. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
6. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.
Franco M; Man S; Chen L; Emmenegger U; Shaked Y; Cheung AM; Brown AS; Hicklin DJ; Foster FS; Kerbel RS
Cancer Res; 2006 Apr; 66(7):3639-48. PubMed ID: 16585189
[TBL] [Abstract][Full Text] [Related]
7. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
[TBL] [Abstract][Full Text] [Related]
8. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
[TBL] [Abstract][Full Text] [Related]
9. Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy.
Paez-Ribes M; Man S; Xu P; Kerbel RS
Clin Cancer Res; 2015 Dec; 21(24):5488-98. PubMed ID: 26169967
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic drugs increase xenograft aggressiveness.
Cancer Discov; 2012 Mar; 2(3):OF3. PubMed ID: 22586000
[TBL] [Abstract][Full Text] [Related]
11. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents.
Zhang Q; Bindokas V; Shen J; Fan H; Hoffman RM; Xing HR
Mol Cancer Ther; 2011 Jul; 10(7):1173-84. PubMed ID: 21586628
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
[TBL] [Abstract][Full Text] [Related]
13. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
14. Resolution of Spatial and Temporal Heterogeneity in Bevacizumab-Treated Breast Tumors by Eigenspectra Multispectral Optoacoustic Tomography.
Liapis E; Klemm U; Karlas A; Reber J; Ntziachristos V
Cancer Res; 2020 Dec; 80(23):5291-5304. PubMed ID: 32994204
[TBL] [Abstract][Full Text] [Related]
15. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
[TBL] [Abstract][Full Text] [Related]
16. Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice.
Lignet F; Benzekry S; Wilson S; Billy F; Saut O; Tod M; You B; Adda Berkane A; Kassour S; Wei MX; Grenier E; Ribba B
J Theor Biol; 2013 Mar; 320():86-99. PubMed ID: 23261980
[TBL] [Abstract][Full Text] [Related]
17. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.
Dings RP; Loren M; Heun H; McNiel E; Griffioen AW; Mayo KH; Griffin RJ
Clin Cancer Res; 2007 Jun; 13(11):3395-402. PubMed ID: 17545548
[TBL] [Abstract][Full Text] [Related]
18. A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab Resistance.
Tosca EM; Rocchetti M; Pesenti E; Magni P
Cancer Res; 2020 Feb; 80(4):820-831. PubMed ID: 31818849
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic therapy: creating a unique "window" of opportunity.
Lin MI; Sessa WC
Cancer Cell; 2004 Dec; 6(6):529-31. PubMed ID: 15607955
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
Winkler F; Kozin SV; Tong RT; Chae SS; Booth MF; Garkavtsev I; Xu L; Hicklin DJ; Fukumura D; di Tomaso E; Munn LL; Jain RK
Cancer Cell; 2004 Dec; 6(6):553-63. PubMed ID: 15607960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
